Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2010 October;58(5) > Minerva Cardioangiologica 2010 October;58(5):531-42





A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695




Minerva Cardioangiologica 2010 October;58(5):531-42


language: English

Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia

Salgado B. J. 1, 2, Salgado J. V. 3, Dos Santos A. M. 4, Casulari L. A. 5

1 Endocrinology and Diabetes Service University Hospital, Federal University of Maranhão, São Luís, Brazil; 2 Department of Physiology, Federal University of Maranhão, São Luís, Brazil; 3 Clinical Chemistry Service, University Hospital Federal University of Maranhão, São Luís, Brazil; 4 Department of Public Health, Federal University of Maranhão, São Luís, Brazil; 5 Endocrinology Service, University of Brasilia Brasilia, Brazil


AIM: The aim of this study was to evaluate the effects of low-dose niacin extended-release (niacin-ER) combined with simvastatin (SV) in the treatment of patients with mixed dyslipidemia who have not normalized their lipid profile with statin therapy alone.
METHODS: A prospective, clinical trial of 35 patients with mixed dyslipidemia who were treated with niacin-ER and SV. The dosage administrated were 250 mg niacin-ER plus 10 mg SV in the first two weeks, 500 mg/20 mg in the next two weeks, and 750 mg/20 mg in the final four weeks. Patients received 200 mg of acetylsalicylic acid 30 minutes before each drug administration.
RESULTS: There were significant increases of apolipoprotein A-I and HDL; and decrease of apolipoprotein B, LDL, triglycerides, and total cholesterol. There was low frequency of flushing (10%) and no worsening in the control of fasting and postprandial glycemia and glycated hemoglobin.
CONCLUSION: Low-dose niacin-ER associated to simvastatin may be useful for achieving improvement in lipid profile or even to achieve the targets recommended for prevention of cardiovascular disease. Other advantages are the low frequency of flushing, which improved adherence to treatment, and no worsening of insulin resistance in patients with or without diabetes mellitus.

top of page

Publication History

Cite this article as

Corresponding author e-mail